Researchers from Boston Children’s Hospital and Dana-Farber Cancer Institute reported an approach for hematopoietic stem/progenitor cell transplants that aims to replace genotoxic conditioning. Their epitope-editing strategy uses antibodies to selectively deplete patient stem cells while sparing edited donor cells, with results described in Nature as a potentially less toxic path for broader HSCT and gene therapy use.